Abeona Therapeutics Inc (ABEO) Receives Average Rating of “Buy” from Brokerages

Abeona Therapeutics Inc (NASDAQ:ABEO) has received an average recommendation of “Buy” from the twelve analysts that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and eight have given a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $26.88.

Several analysts have commented on the stock. ValuEngine upgraded shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 5th. BidaskClub upgraded shares of Abeona Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, February 4th. Mizuho reiterated a “buy” rating and set a $17.00 target price on shares of Abeona Therapeutics in a research report on Monday, December 10th. Cantor Fitzgerald reiterated a “buy” rating and set a $36.00 target price on shares of Abeona Therapeutics in a research report on Thursday, December 6th. Finally, HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of Abeona Therapeutics in a research report on Thursday, February 21st.

Shares of Abeona Therapeutics stock traded up $0.68 on Friday, hitting $8.10. 657,049 shares of the company’s stock traded hands, compared to its average volume of 399,426. The stock has a market capitalization of $388.35 million, a price-to-earnings ratio of -12.27 and a beta of 1.93. Abeona Therapeutics has a one year low of $6.26 and a one year high of $22.00.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Northern Trust Corp lifted its position in shares of Abeona Therapeutics by 28.2% during the 2nd quarter. Northern Trust Corp now owns 390,342 shares of the biopharmaceutical company’s stock valued at $6,246,000 after buying an additional 85,908 shares in the last quarter. SG Americas Securities LLC purchased a new position in Abeona Therapeutics in the 3rd quarter valued at $235,000. BlackRock Inc. lifted its holdings in Abeona Therapeutics by 1.6% in the 3rd quarter. BlackRock Inc. now owns 2,220,116 shares of the biopharmaceutical company’s stock valued at $28,418,000 after purchasing an additional 35,610 shares in the last quarter. FMR LLC lifted its holdings in Abeona Therapeutics by 1.4% in the 3rd quarter. FMR LLC now owns 7,191,492 shares of the biopharmaceutical company’s stock valued at $92,051,000 after purchasing an additional 97,185 shares in the last quarter. Finally, Trexquant Investment LP purchased a new position in Abeona Therapeutics in the 3rd quarter valued at $163,000. Institutional investors and hedge funds own 67.93% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Recommended Story: What is Liquidity?

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.